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INTRODUCTION 
 
      Acquired Immuno Deficiency Syndrome was first documented in the 
United States in the year 1981 when the U.S Center for Disease Control and 
prevention (CDC) reported incidence of Pneumocystis jiroveci pneumonia in 
five previously healthy homosexual men. Within months, disease was 
recognized in injection drug users (IDUs), in people who received blood 
transfusions and patients with hemophilia1. 
 
       Human Immuno Deficiency Virus was isolated from a patient who had 
lymphadenopathy in the year 1983 and in 1984 it was found clearly to be the 
causative organism of AIDS.  India's first case of AIDS was reported in 1986 
from Chennai2. 
 
       HIV was isolated first at autopsy and later by non invasive techniques 
that cardiac manifestations can be caused by HIV infection. The reported 
frequency of cardiac abnormalities in PLHIV depends on the population 
under study and the definition of cardiac abnormality. 
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       Prior to the advent of Anti-retroviral therapy (ART), clinically significant 
cardiac disease was present in  almost all patient with HIV infection and was 
detected in most cases during postmortem. Cardiac abnormalities in AIDS 
patients appear to be more common than previously contemplated. When 
PLHIV were examined by echocardiography in late 1990, cardiac diseases 
were detected more often than could be expected from clinical symptoms and 
physical examination. Most conditions are clinically quiescent but some may 
have devastating and fatal outcomes. Pericardial effusion and Myocarditis are 
among the most commonly reported abnormalities though cardiomyopathy, 
endocarditis and coronary vasculopathy have also been reported.  
 
        It is expected that the risk of cardiac and cardiovascular disease will rise 
in the following years due to the cardiovascular risk profile and increased life 
expectancy of infected patients. Therefore diagnosis and therapy of HIV 
associated cardiovascular diseases should be an inherent part of current 
therapeutic concepts of HIV infection. 
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AIM OF THE STUDY 
 
 
 
 
 
1.  To study the prevalence of cardiac abnormalities in HIV 
infected individuals. 
 
2.  To correlate the cardiac abnormalities with stage of infection. 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY 
GLOBAL SCENARIO OF HIV3 
According to the UNAIDS report 2015, the HIV prevalence worldwide 
was 36.7 million (34 million-39.8 million) and the estimate of new HIV 
infections is 2.1 million(1.8 million-2.4 million).  
The incidence of HIV infection among adults is remaining static in the 
recent era as compared  with earlier data. 
 
Prevalence of PLWHA on ART, global 2010 to 2015 
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INDIAN SCENARIO OF HIV4 
The India HIV Estimation 2015 report states that the National adult 
(15–49 years) HIV prevalence in India is 0.26% (0.22%–0.32%) in 2015. In 
2015, the prevalence of HIV in adult males is 0.30% while in females it is 
0.22% 
 
Among the States/UTs, in 2015, Manipur has shown the highest 
prevalence of  HIV (1.15%),whish is followed by Mizoram (0.80%), 
Nagaland (0.78%), Andhra Pradesh & Telangana (0.66%), Karnataka 
(0.45%), Gujarat (0.42%)  
 
Goa (0.40%). The other states that have shown estimated adult HIV 
prevalence greater than the national  prevalence (0.26%) are Maharashtra, 
Chandigarh, Tripura and Tamil Nadu , while Odisha, Bihar, Sikkim, Delhi, 
Rajasthan and West Bengal have shown an estimated adult HIV prevalence in 
the range of 0.21– 0.25%. All other States/UTs have levels of adult HIV 
prevalence below 0.20%. 
 
The total number of People Living with HIV (PLHIV) in India is 
estimated at 21.17 lakhs (17.11lakhs–26.49 lakhs) in 2015 which has declined 
when compared with 22.26 lakhs (18.00 lakhs-27.85 lakhs) in 2007.The 
number of children  (< 15 years)  with HIV infection is estimated at 6.54%.  
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India is estimated to have around 86 (56–129) thousand new HIV 
infections in 2015,which has declined when compared with 66% in 2000 and 
32% in 2007,the baseline year according to NACP-IV. Adults constituted 
88% (75.9 thousand) of total new infections while children accounted for 
12% (10.4 thousand) of total new infections were among adults (15+years). 
Telangana & Andhra Pradesh , Gujarat, Uttar Pradesh and Bihar currently 
account for 47% of total new infections among adults with each of these 
States contributing 7500 or more new infections in 2015. 
 
 
SCENARIO IN TAMIL NADU 
According to recently released, India HIV Estimation 2015 report, the 
prevalence of HIV infection in Tamilnadu is greater than the  national 
prevalence  (0.26%).The total number of People Living with HIV in Tamil 
Nadu is 1.43 lakhs. 
 
 
HUMAN IMMUNODEFICIENCY VIRUS 1 
        The origin of HIV is unclear. The most likely scenario is that HIV was 
introduced into human from another primate in Sub-Saharan Africa.  
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ETIOLOGIC AGENT 
        The etiologic agent of AIDS is Human Immuno Deficiency Virus (HIV) 
which belongs to the family of human retroviruses (Retroviridae) and the sub 
families of lentiviruses. There are two sub types of HIV namely HIV-1 and 
HIV 2. They are cytopathic viruses. HIV-2 is more similar to SIV (Simian 
Immuno Deficiency Virus) than HIV-1 and it is much less virulent usually 
not resulting in full blown AIDS, but still fatal. 
 
MORPHOLOGY OF HIV   
Electron microscopy shows that the HIV is a spherical enveloped virus, 
about 90 - 120 nm in size.Its basic structure constitutes an outer envelope, 
HIV matrix proteins and viral core. The outer envelope is made up of lipid 
bilayer in which the envelope proteins are embedded, namely glycoprotein 
120(gp 120) and gp 41.The glycoprotein gp 120 is the main protein involved 
in the attachment of the virion to the host cell while gp 41 participates in cell 
fusion process.The core virus particle is composed of ribonucleoproteins. The  
virion contains two single stranded RNA surrounded by the capsule protein 
p24.The HIV matrix proteins are found between the HIV envelope and the 
viral core. 
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Structure Of HIV Virion 
HIV GENOME  
            HIV-1 has the following genes. gag – encodes the proteins that form 
the core of virion. pol – encodes viral enzymes necessary for replication, 
reverse transcriptase, integrase and protease and env – encodes glycoprotein. 
It also contains atleast six other genes tat, rev, nef, vpr, vpu which code for 
proteins involved in the regulation of gene expression. The major difference 
between the genomes of HIV-1 and HIV-2 is the fact that HIV-2 lacks the 
vpu gene and has vpx gene which is not present in HIV-1.  
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LIFE CYCLE 
 
 
 
 
 
ATTACHMENT AND ENTRY 
            The replication cycle of HIV begins with the high affinity binding of 
the gp 120 protein via a portion of its V1region near the N terminus to its 
receptor on the host cell surface, the CD4 molecule. It is also expressed on 
the surface of monocytes and dendrites / langerhans cells.The envelope 
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protein gp 120 binds to CD4 and undergoes a conformational change that 
facilitates binding to one of a group of co-receptors. CCR5 and CXCR4 
constitute the two major co-receptors. 
 
 REVERSE TRANSCRIPTION AND INTEGRATION  
           Following binding of the envelop protein to the CD4 molecule, the 
virus is “uncoated” and the viral RNA is converted into complementary DNA 
(C-DNA) by virion associated reverse transcriptase enzyme. The C-DNA is 
transported to the host cell nucleus and eventually gets incorporated into the 
host cell chromosomes by virus specific integrase enzyme.  
 
TRANSCRIPTION, TRANSLATION AND REPLICATION 
            The integrated DNA is transcribed into messenger RNA (mRNA) 
which comes out into cytoplasm and viral proteins are synthesized using 
protein synthesizing machinery and raw material from the host cell. Some of 
the viral proteins are synthesized as polyproteins that are eventually cleared 
by the proteinase enzyme. 
 
MATURATION AND RELEASE  
            Newly synthesized progeny RNA and proteins are packaged together 
and the newly formed virus particles are released from the infected cell by the 
budding process.  
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PROGRESSION OF ILLNESS1 
 The median time from primary HIV infection to the development of 
AIDS in untreated individuals is approximately 10 years. Long term survivors 
are those who survive for >= 20 years after initial infection. It may be related 
to beneficial effect of ART and prophylaxis against opportunistic infections. 
Long term nonprogressors are those who have been infected with HIV for ≥ 
10 years without decline in the CD4 count below the normal range and who 
are not on ART. 
The reasons being 
 1. Mutant nef gene of HIV  
2. Heterozygosity for CCR5- ∆32 deletion  
3. Heterozygosity for CCR2-64I mutation  
4. Homozygosity for SDF1-3’A mutation  
5. Heterozygosity for the RANTES-28G mutation 11 
 
CLASSIFICATION 1 
  1993 Revised classification system for HIV infection and expanded 
AIDS surveillance case definition for adolescents and adults. 
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PGL – Progressive Generalized Lymphadenopathy HIV infected persons 
classified in A3, B3, C1, C2 and C3 are AIDS cases. 
 
“ Category A:  
      One or more of the following conditions in adolescents or adults (> 13 
years) with documented HIV infection. Conditions listed in categories B and 
C must not have occurred.  
1. Asymptomatic HIV infection  
2. Progressive Generalized Lymphadenopathy 
 3. Acute (primary) HIV infection with accompanying illness or history of 
acute HIV infection. 
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Category B:  
   Consists of symptomatic conditions in an HIV infected adolescent or adult 
that are not included among conditions listed in clinical category C and that 
meets one of the following criteria  
1. The conditions are attributed to HIV infection or are indicative of a defect 
in cell mediated immunity (CMI). 
 2. Conditions are considered by physicians to have a clinical course or to 
require management that is complicated by HIV infection. Examples 
include, but are not limited to the following.  
    a. Bacillary angiomatosis 
    b. Candidiasis, oropharyngeal (thrush) 
    c. Candidiasis, vulvovaginal: persistent, frequent or poorly responsive to 
therapy  
    d. Cervical dysplasia (moderate or severe) / cervical carcinoma in situ 
     e. Constitutional symptoms, fever or diarrhea lasting > 1 month 
     f. Oral hairy leukoplakia  
     g. Herpes zoster involving atleast 2 distinct episodes or more than one 
dermatome  
     h. Idiopathic thrombocytopenic purpura  
     i. Listeriosis  
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     j. Pelvic inflammatory disease, particularly complicated by tuboovarian 
abscess 
     k. Peripheral neuropathy  
 
Category C:  
    Conditions listed in AIDS surveillance case definition  
     a. Candidiasis of bronchi, trachea or lungs  
     b. Candidiasis, esophageal  
     c. Cervical cancer, invasive  
     d. Coccidioidomycosis, disseminated or extrapulmonary  
     e. Cryptococcosis, extrapulmonary  
     f. Cryptosporidiosis, chronic intestinal (> 1 month’s duration)  
     g. Cytomegalovirus disease (other than liver, spleen or nodes)  
     h. Cytomegalovirus retinitis (with loss of vision) 
     i. Encephalopathy, HIV related  
     j. Herpes simplex: chronic ulcers (> 1 month’s duration) or bronchitis, 
pneumonia or esophagitis  
     k. Histoplasmosis, disseminated or extra pulmonary  
     l. Isosporiasis, chronic intestinal (> 1 month’s duration)  
    m. Kaposi’s sarcoma  
    n. Lymphoma, Burkitt’s (or equivalent term)  
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   o. Lymphoma, primary of brain  
    p. Mycobacterium avium complex or M. kansasii, disseminated or 
extrapulmonary  
    q. Mycobacterium tuberculosis, any site (pulmonary or extra pulmonary)  
    r. Mycobacterium, other species or unidentified species, disseminated  
    s. or extrapulmonary  
    t. Pneumocystis jiroveci pneumonia  
   u. Pneumonia, recurrent  
   v. Progressive multifocal leukoencephalopathy  
   w. Salmonella septicemia, recurrent 
    x. Toxoplasmosis of brain 
    y. Wasting syndrome due to HIV” 
 
CLASSIFICATION OF HIV INFECTION (WHO CLINICAL 
STAGING SYSTEM) 7 
 
Clinical stage 1:  
a. Asymptomatic  
b. Persistent Generalized Lymphadenopathy  
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Clinical stage 2: 
a. Weight loss <10% of body weight 
b. Recurrent upper respiratory tract infections (e.g. bacterial sinusitis) 
c. Herpes zoster 
d. Angular cheilitis 
e. Recurrent oral ulceration 
f. Papular pruritic eruptions 
g. Seborrhoeic dermatitis 
h. Fungal nail infections 
 
Clinical stage 3: 
 a. Weight loss > 10% of body weight  
b. Unexplained chronic diarrhea > 1 month 
 c. Unexplained persistent fever (intermittent or constant) > 1 month  
d. Persistent Oral Candidiasis (thrush)  
e. Oral hairy leukoplakia  
f. Pulmonary tuberculosis 
 g. Severe bacterial infections (e.g. pneumonia, pyomyositis) 
 h. Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis  
i. Unexplained anemia (< 8 g / dl), neutropenia (< 0.5 X 109 / litre) and or 
chronic thrombocytopenia  
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Clinical stage 4:  
a. HIV wasting syndrome  
b. Pneumocystis jiroveci pneumonia  
c. Recurrent severe bacterial pneumonia  
d. Toxoplasmosis of the brain  
e. Chronic Cryptosporidiosis  
f. Chronic Isosporiasis  
g. Cryptococcosis - extrapulmonary  
h. Cytomegalovirus infection (retinitis or infection of other organs) 
 i. HIV Encephalopathy 
 j. Chronic Herpes simplex infection (orolabial, genital or anorectal of > 1 
month’s duration or visceral at any site) 
 k. Disseminated endemic mycosis (Extrapulmonary Histoplasmosis, 
Coccidiomycosis)  
l. Kaposi’s sarcoma  
m. Candidiasis - esophagus, trachea, bronchi or lungs  
n. Disseminated non-tuberculous mycobacteria infection  
o. Mycobacterium tuberculosis, extrapulmonary  
p. Progressive multifocal leukoencephalopathy  
q. Recurrent septicemia (including non typhoid salmonella septicemia) 
 r. Lymphoma (Cerebral or B cell Non-Hodgkin)  
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s. Invasive cervical carcinoma 
 t. Atypical disseminated leishmaniasis 
 u. Symptomatic HIV-associated nephropathy or symptomatic HIV associated 
cardiomyopathy  
  
WHO CASE DEFINITION FOR AIDS SURVEILLANCE IN ADULT 
WHERE HIV TESTING FACILITIES NOT AVAILABLE 7 
  Case definition for AIDS is fulfilled if at least two major signs and one 
minor sign are present 
 Major signs:  
a. Weight loss > 10% of body weight  
b. Chronic diarrhea > 1 month  
c. Prolonged fever > 1 month  
Minor signs:  
a. Persistent cough > 1 month 
 b. History of herpes zoster 
 c. Oropharyngeal candidiasis  
d. Generalized lymphadenopathy  
e. Chronic progressive herpes simplex infection  
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 WHO GUIDELINES FOR INITIATION OF ART IN ADULTS AND 
ADOLESCENTS 7 
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NACO GUIDELINES FOR INITIATION OF ART IN ADULTS AND 
ADOLESCENTS6 
 
  * If CD4 count is between 200- 250, this should be repeated in four weeks 
and treatment to be considered in asymptomatic patients. 
     British HIV association (BHIVA) suggests initiation of ART for 
asymptomatic HIV infected individuals having less than 200 CD4 T cell 
counts.70 International AIDS society recommends initiation of ART in 
asymptomatic individuals with CD4 count > 200 to 350 cells / µl and viral 
load 50000 - 100000 copies / ml. 
    In a study by Ramalingam et al, conducted in 2001 have shown that mean 
CD4 counts in south Indian population both normal and HIV infected 
individuals are lower than in western population and have proposed a 
modified classification based on CD4 cell count for south Indians. The 
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categories of CD4 count proposed were cell count > 300,  81 - 300, ≤ 80 cells 
/ µL, instead of the ≥ 500, 201-499, ≤ 200 recommended by CDC(Centre for 
Disease Control and prevention). 
     Kannagai et al study conducted in 2008 has shown that majority of HIV 
infected individuals in South India with CD4 counts of 200 - 350 cells / µL 
had higher viral load than that suggested by International AIDS Society. 
 
 CARDIAC MANIFESTATIONS IN HIV INFECTED INDIVIDUALS  
The reasons for the paucity of knowledge about the etiology of HIV 
associated cardiovascular diseases are 
 1. In the early years of AIDS epidemic, most patients died of infectious 
complications, before the manifestations of cardiovascular 
complications.  
 
2. Because cardiomyocytes do not have CD4 receptors, the heart was 
thought to be unaffected by HIV infection.  
 
3. Presence of cardiovascular risk factors like poor nutrition, alcohol and 
drugs that can lead on to cardiac disease in HIV infected individuals.  
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4. Cardiac disease remains relatively asymptomatic in early stages of HIV 
infection.   
 
5. Heart disease can be overlooked in HIV-positive patients, because 
symptoms of breathlessness, fatigue and poor exercise intolerance are 
frequently ascribed to other conditions associated with HIV infection.  
 
Around 40% of HIV infected patients are found to have cardiac disease 
at autopsy and 25% of patients with AIDS have lesions detectable by 
echocardiography. Many of these lesions are mild, and HIV related heart 
disease probably causes symptoms in less than 10% and death in less than 2% 
of all patients with HIV infection. 
 
     At the beginning of the epidemic, heart muscle disease was the dominant 
cardiac complication of HIV infection in developed world, and tuberculous 
pericarditis in Africa. The advent of HAART (highly active anti-retroviral 
therapy) has changed the pattern of disease in developed countries where 
premature coronary artery disease and other manifestations of atherosclerosis 
are now the most common cardiovascular disorder.  
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This is partly caused by HAART-induced metabolic problems, particularly 
insulin resistance and hyperlipidemia, but also reflects a high prevalence of 
conventional risk factors such as smoking. 
 
     Most of the cardiac problems associated with HIV are due to advanced 
immunodeficiency and are found mainly in developed countries due to poor 
accesss of anti-retroviral therapy. 
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CARDIAC MANIFESTATIONS OF HIV/AIDS8 
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CARDIOVASCULAR ASSESMENT OF THE HIV/AIDS PATIENT  
        Heart disease can be overlooked in HIV-positive patients, because 
symptoms of breathlessness, fatigue and poor exercise intolerance are 
frequently ascribed to other conditions associated with HIV infection. 
Echocardiographic assessment of HIV patients is extremely useful and can be 
used to identify those cardiac conditions that can be associated with poor 
outcome: pericardial effusion,left ventricular (LV) systolic dysfunction / heart 
muscle disease,intracardiac masses. 
 
INDICATIONS FOR ECHOCARDIOGRAPHIC ASSESSMENT OF 
HIV POSITIVE PATIENTS 8 
 1) Possible baseline assessment at the time of diagnosis of HIV infection  
2) Base line assessment and 1 - 2 yearly monitoring of patient with 
 i) Clinical manifestations of possible cardiac involvement  
• Unexplained dyspnea / hypoxia  
• Third heart sound, inappropriate tachycardia  
• Raised jugular venous pressure  
• Peripheral edema / right heart failure 
• Radiographic evidence of cardiomegaly 
   ii) Viral Coinfection  
• Cytomegalovirus  
• Epstein-Barr virus  
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•  Coxsackie virus 
•  Adeno virus  
   iii) History of preexisting cardiac disease  
•  Left ventricular systolic dysfunction (any cause)  
• Valvular heart disease  
• Suspicion of infective endocarditis in intravenous drug users  
   iv) High-risk HIV patients with:  
• Wasting and Encephalopathy  
• CD4 count < 100 cells / mm3 or AIDS  
• Potentially cardiotoxic medications  
• Multiple hospitalizations  
3) Possible 1-2 yearly monitoring of asymptomatic HIV positive patients  
4) Frequent assessment of HIV positive patients with cardiovascular 
involvement (as guided by cardiologist) 
  
HIV/AIDS AND THE PERICARDIUM  
             Pericardial effusion and pericarditis are the most common 
abnormalities found in early HIV/AIDS autopsy studies. Effusions are 
generally small and asymptomatic.  
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             Pericardial effusion may be related to an opportunistic infection, 
metabolic abnormality or malignancy, but most often a clear etiology is not 
found. The effusion is often part of a generalized serous effusive process also 
involving pleural and peritoneal surfaces. This capillary leak syndrome may 
be related to enhanced cytokine production in the later stages of HIV disease. 
Other causes can include uremia from HIV-associated nephropathy. Effusion 
markedly increases the mortality. 
 
            Screening echocardiography is recommended for HIV-infected 
individuals regardless of the stage of the disease. Patients should undergo 
pericardiocentesis if they have pericardial effusion and clinical signs 
(elevated jugular venous pressure, dyspnea, hypotension, persistent 
tachycardia, pulsus paradoxus) or Echocardiographic signs of tamponade 
(Continuous Wave Doppler evidence of respiratory variation in valvular flow, 
septal bounce, right ventricular collapse, a large effusion). 
 
Patients with pericardial effusion without tamponade should be 
evaluated for treatable opportunistic infections, such as tuberculosis and for 
malignancy. Repeated echocardiography is recommended after one month or 
sooner if clinical symptoms direct. 
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HIV/AIDS AND THE MYOCARDIUM  
MYOCARDITIS 
            Numerous pathologic studies have confirmed the presence of varying 
histologic patterns of lymphocytic myocarditis in HIV patients.15 As such, 
estimates of the prevalence of myocarditis in HIV/AIDS varies from 53% 16 
in the pre-HAART era to much lower levels today in the developed world. 
 
 There are several hypotheses regarding the etiology of myocarditis in 
AIDS including:  
1) Primary HIV myocarditis  
2) Secondary HIV myocarditis  
3) Opportunistic infections  
4) Autoimmunity 
 
 1) Primary HIV Infection of the Myocardium  
            HIV neither has been universally accepted nor unambiguously proven 
causative agent of myocarditis in AIDS. Although HIV can clearly infect 
monocytes/macrophages and myocardial interstitial cells, evidence proving 
that HIV can infect human cardiac myocytes which do not possess CD4 
receptor is less clear. 
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            HIV gene sequences have been detected by PCR in microdissected 
endomyocardial biopsies from HIV-positive patients some of whom had 
cardiac symptoms. HIV has also been shown gain entry into human fetal 
cardiac myocyte by ingestion through a specific crystallizable fragment (of 
immunoglobulin) (Fc) receptor, and it remains possible that this or other, 
unidentified mechanisms can promote HIV entry into the myocyte and 
facilitate a primary HIV myocarditis. 
 
2) Secondary HIV Myocarditis  
                 Interstitial lymphocytes and macrophages can form contact with 
myocytes causing focal loss of basement membrane through a local 
reaction.20 Proteolytic enzymes released through HIV replication in the 
interstitium could also damage myocytes. The HIV envelope glycoprotein 
group 120 can induce tumor necrosis factor-α (TNF-α) expression from 
macrophages and has been shown to enhance IL-1induced nitric oxide 
production in neonatal rat cardiac myocytes. Cytokine IL-6 which has some 
effect on immune response and viral replication in murine myocarditis, has 
been found in excess in small number of HIV-positive patients with biopsy 
proven myocarditis. 
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3) Myocardial Opportunistic Infections in HIV/AIDS  
               Autopsy has confirmed a variety of opportunistic infections of the 
myocardium in patients with AIDS. Infectious agents included Toxoplasma 
gondii, Cryptococcus, cytomegalovirus, Candida, Pneumocystis jiroveci, 
Microsporidium, Histoplama capsulatum, Atypical mycobacteria and 
Aspergillus organisms involving the myocardium. 
 
 4) Autoimmunity  
                 Many autoimmune processes have been described in association 
with HIV/AIDS infection. HIV infection can itself trigger autoimmune 
phenomenon in susceptible patients. The presence of auto antibodies along 
with hypergammaglobulinemia and elevated circulating immune complexes 
suggests that yet unidentified autoimmune process can take place in HIV 
positive patients. 
 
           The symptoms of myocarditis are protean and include fatigue, dyspnea 
and pleuritic chest pain. The signs are unexplained tachycardia, third heart 
sound or a friction rub. ECG may show nonspecific conduction defects, 
repolarization abnormalities and ST-T wave changes, although these are not 
invariable.  
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Chest radiograph can be normal or suggest cardiac enlargement with 
pulmonary congestion. Echocardiography is usually non diagnostic but can 
show hyperdynamic LV function in HIV-positive children or occasionally LV 
dyskinesia in adult AIDS patients. 
 
 DILATED CARDIOMYOPATHY AND LEFT VENTRICULAR 
DYSFUNCTION IN HIV/AIDS  
             The prevalence of heart muscle disease appears to be approximately 
4.4% for dilated cardiomyopathy and 6.4% for isolated LV dysfunction and 
the condition can cause symptoms in up to 5.5% of HIV/AIDS patients. The 
presence of dilated cardiomyopathy is ominous and associated with poor 
survival compared to patients with structurally normal hearts. This poor 
outlook remained true even after correcting CD4 counts. 
 
 Mechanisms of Cardiomyopathy in HIV/AIDS  
              The mechanisms for the development of LV dysfunction, 
cardiomyopathy in AIDS remain unclear. In addition to the role of HIV, 
lymphocytic myocarditis, cytokines and autoimmune responses, the 
contributions of illicit and prescribed medications, nutritional deficiencies 
and other factors also appears to be pathogenetically or pathophysiologically 
important. 
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 Drug Induced Heart Muscle Disease  
              Zidovudine and other Nucleoside Reverse Transcriptase Inhibitors 
(NRTIs) can be implicated in the development of some cases of heart muscle 
disease. In addition to inhibiting HIV reverse transcriptase, the  drug causes a 
dose dependent reversible skeletal myopathy by altering mitochondrial DNA 
replication. Foscarnet in CMV infection associated with reversible congestive 
cardiac failure as has doxorubicin and interferon-α therapy in Kaposi’s 
sarcoma. The effect of recreational drugs like cocaine use has been associated 
with myocarditis and a possibly reversible dilated cardiomyopathy in non-
AIDS patients should be considered in the HIV population. 
 
Nutritional Deficiencies and Cardiac Dysfunction in HIV/AIDS    
             HIV/AIDS patients with evidence LV systolic dysfunction should be 
assessed for micro nutrient deficiency, which is common in HIV infected 
individuals. Abnormally low levels of selenium and antioxidants have been 
demonstrated and oxidative stress can be an important mechanism for cellular 
damage in AIDS. Selenium deficiency is implicated in the pathogenesis of 
Keshan disease, a specific form of dilated cardiomyopathy in China, which 
can respond to dietary supplementation. In the same way, decreased selenium 
content has been demonstrated in the hearts of AIDS patients. 
 
 
34 
 
 
              L- Carnitine deficiency has also been described in HIV patients, 
possibly in association with cardiac symptoms and in whom supplementation 
can be advantageous. Experimentally, Carnitine administration reversed 
myopathic changes induced by Zidovudine (AZT) in vitro, but the clinical 
effects have yet to be established.  
 
              The echocardiographic features of dilated cardiomyopathy is global 
LV systolic dysfunction with the consistent feature of reduced ejection 
fraction. LV dilatation can result in mitral valve distortion and lead to 
regurgitation. In AIDS patients, mitral regurgitation has also been described 
with infective endocarditis. Abnormalities of mitral flow, specifically reduced 
early mitral peak velocity (E) and other indices of diastolic dysfunction have 
been noted early in the course of HIV/AIDS with normal ejection fraction and 
in association with LV systolic dysfunction. 
 
             No randomized trials have been reported regarding the effectiveness 
of current heart failure therapies in people with HIV/AIDS.9 Common agents 
such as diuretics, aldosterone antagonists, and digoxin can improve well 
being. Angiotensin inhibitors can be poorly tolerated, possibly because many 
patients already have low systemic vascular resistance. Etarnacept, 
pentoxifylline have been used in severe heart failure with some success. 
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               Intravenous immunoglobulin therapy has been used successfully in 
children with symptomatic HIV heart muscle disease and can be protective  
against the development of LV dysfunction in that group. The use of cardiac 
resynchronization therapy has not been described in HIV population, 
although case reports of successful use of LV assist devices and orthotopic 
heart transplant exist, although these are uncommon.  
 
NONBACTERIAL THROMBOTIC ENDOCARDITIS 
              Marantic or nonbacterial thrombotic endocarditis (NBTE) is a 
condition in which friable clumps of platelets and red cells adhere to the 
cardiac valves. Unlike bacterial endocarditis these lesions are not infective 
and show no evidence of an inflammatory reaction.  
 
              The pathogenesis is not fully understood, but hypercoagulability, 
immune complex deposition, or specific vitamin deficiency can be important 
in conjunction with endothelial damage from intravenous catheters or injected 
particulate matters. Any heart valve can be affected and frequently multiple 
lesions are found on different levels. 
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           Treatment should focus on reducing the underlying disease causing 
coagulation abnormalities, valvular endothelial damage or both. An 
anticoagulation risk benefit assessment must be made on individual basis. 
 
INFECTIVE ENDOCARDITIS 
            The immunological abnormalities associated with HIV render patients 
susceptible to bacterial infections. The clinical presentation is  same for both 
HIV positive and negative patients but runs a more fulminant course in later 
stages of AIDS. The most common valve involved is the tricuspid valve as 
with infective endocarditis in HIV negative intravenous drug users. Most 
frequently isolated organisms include staphylococcus aureus, salmonella 
species, streptococcus viridans but fungal endocarditis can occur in end-stage 
AIDS. Antimicrobial treatment may have to be widened. Operative 
indications include hemodynamic instability, failure to sterilize blood cultures 
after appropriate intravenous antibiotics and severe valvular destruction in 
patients with reasonable life expectancy after recovery from surgery. 
 
CARDIAC TUMORS IN HIV/AIDS  
            Kaposi’s sarcoma (KS) is the most common AIDS related neoplasia; 
there is often widespread and potentially fatal visceral involvement in HIV- 
positive individuals. The prevalence of cardiac Kaposi’s sarcoma appears to 
have decreased significantly since early reports. 
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           It's not usually associated with symptoms of cardiac dysfunction; but 
cases of fatal tamponade associated with the tumor have been reported, and 
heart failure without ventricular dilatation can occur in cases with extensive 
myocardial infarction.8 Kaposi’s sarcoma can be treated with daunorubicin, 
doxorubicin or related anthracyclines. Liposomal  encapsulated daunorubicin 
has an improved pharmacological profile and can therefore be preferred in 
patients with Kaposi’s sarcoma and AIDS. 
 
              Non Hodgkin’s Lymphoma (NHL) can involve the pericardium or 
myocardium. Cardiac lymphoma commonly gives rise to clinical symptoms 
of tamponade, heart failure, and conduction abnormalities or superior vena 
cava syndrome. Systemic chemotherapy with or without concomitant 
radiation or surgery has been beneficial in some patients, but overall the 
prognosis is poor. 
 
RIGHT VENTRICULAR DYSFUNCTION  
             Isolated right ventricular dysfunction without pulmonary 
hypertension is of unknown significance and can be related to changes in 
pulmonary circulation. Therefore bronchopulmonary infections should be 
treated aggressively and intravenous drug use, which can result in micro 
vascular pulmonary emboli should be discouraged. 
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PULMONARY HYPERTENSION  
Primary pulmonary hypertension is estimated to occur in 0.5% of 
hospitalized AIDS patients. Although pulmonary hypertension can be related 
to the action of viral proteins or the action of cytokines on the endothelial 
cell, characteristic pulmonary arteriopathy is found in HIVrelated pulmonary 
hypertension. Right heart catheterization can be worthwhile to determine if 
pulmonary hypertension can be reversed and has been used in HIV patients. 
HAART itself can be beneficial in terms of outcome in pulmonary 
hypertension  but agents like bosentan, epoprostenol, treprostinil  or sildenafil 
can improve feeling of well being without altering prognosis.  
 
ACCELERATED ATHEROSCLEROSIS 
              Accelerated atherosclerosis has been observed in young HIVinfected 
adults and children without traditional coronary risk factors. Protease 
inhibitor therapy markedly alters lipid metabolism and can be associated with 
premature atherosclerotic disease. Chronic inflammatory states have also 
been associated with atherosclerotic disease. Atherosclerotic disease is 
believed to have multi factorial causes and is prone to plaque rupture, 
possibly related to the host environment. 
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Lipodystrophy should be recognized and treated because of an elevated 
10 year cardiovascular risk. Risk stratification based on traditional risk 
factors plus diet, alcohol intake, physical exercise, hypertriglyceridemia, 
cocaine use, heroin use, thyroid disease, renal disease and hypogonadism 
should be considered for long term cardiac preventive care. 
 
VASCULITIS  
            Most types of vasculitis have been reported in HIV-infected patients. 
Vasculitis should be suspected in patients with fever of unknown origin, 
unexplained multi system disease, arthritis or myositis, glomerulonephritis, 
peripheral neuropathy (especially mononeuritis multiplex) and unexplained 
gastrointestinal, cardiac or central nervous system ischemia. 
Immunomodulatory therapy, chiefly with systemic corticosteroid therapy has 
been successful. 
 
AUTONOMIC DYSFUNCTION  
Early signs of autonomic dysfunction include syncope and presyncope, 
diminished sweating, diarrhea, bladder dysfunction and impotence. Patients 
with HIV - associated nervous system disease have the greatest abnormalities 
in autonomic function. 
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DISORDERS OF RHYTHM  
            Sudden death and rhythm abnormalities are common in HIV infection 
and account for 20% of cardiac related death in this group of patients. These 
can be secondary to other cardiac pathology or be a consequence of some 
forms of treatment like pentamidine induced torsade de pointes ventricular 
tachycardia. HIV infection itself is associated with QT prolongation and 
torsades de pointes ventricular tachycardia. The incidence increases with 
progression to AIDS. 
 
            Hepatitis C is independently associated with increased QT duration 
and co infection with HIV nearly doubles the risk.56 Concomitant electrolyte 
abnormalities can be important in development of cardiac arrhythmia. ECG 
abnormalities and rhythm disturbances are not uncommon findings in HIV 
positive patients with myocarditis or heart muscle disease and ectopic beats, 
ventricular tachycardia, and sudden death have also been reported. 
 
 
  
41 
 
 
MATERIAL AND METHODS 
 
Place of study- Department of Internal Medicine, Thanjavur Medical College 
and Hospital  
Collaborating Departments- ART Centre, Department of Cardiology, 
Thanjavur Medical College and Hospital 
Duration of the Study- Jan 2016 to June 2016 
Type of study- Cross- sectional 
 
STUDY POPULATION: 
A total of 100 patients who were sero-positive and who fit the 
inclusion criteria were chosen. An attempt was made to find out whether the 
prevalence of cardiac abnormalities had any relation with the stage of 
infection. 
 
INCLUSION CRITERIA: 
All patients diagnosed to have HIV infection/ AIDS after ELISA test 
being positive were included in the study. 
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EXCLUSION CRITERIA: 
1. Diabetes 
2. Hypertension 
3. Congenital/ acquired heart disease 
4. Dyslipidemia 
 
RISK FACTOR ASSESSMENT QUESTIONNAIRE 
         All HIV infected individuals who were included in this study were 
subjected to a questionnaire to assess the risks of acquiring HIV, risk factors 
for cardiac disease and symptomatology of cardiac illness. 
 
               To assess the risk of acquiring HIV, history regarding their sexual 
exposures, use of intravenous drugs and history of blood transfusion were 40 
asked. The individual’s occupation, marital status, extramarital and premarital 
sexual exposures, history of past and present sexually transmitted infections 
were also noted.The  HAART regimen the individual is currently taking and 
the duration of treatment was also noted. 
 
               To assess the risk factors for cardiac disease, questions regarding 
duration and amount of smoking and alcohol consumption were asked. 
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               To assess the symptoms of cardiac disease questions regarding 
presence of chest pain, breathlessness, palpitation, pedal edema and fatigue 
were asked. Duration of each symptom was also noted. 
 
CLINICAL EXAMINATION: 
               All patients were meticulously examined for the presence of anemia, 
cyanosis, clubbing, pedal edema, dyspnea, jaundice, generalized 
lymphadenopathy and skin and mucous membrane lesions. Respiratory rate, 
pulse rate, jugular venous pressure, blood pressure (both in supine and erect 
posture) were also recorded. A thorough clinical examination of the 
cardiovascular system, respiratory system, abdomen and central nervous 
system was done.  
 
LABORATORY INVESTIGATIONS 
               All of them were subjected to the following investigations. 
 
              Complete blood count, blood urea and sugar, serum creatinine and 
electrolytes, liver function tests (serum bilirubin, alanine transamin ase and 
alkaline phosphatase) and Serum lipid profile were done for all patients.  
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                     A standard 12 lead resting electrocardiogram was taken for all 
individuals in this study.  
 
CD4 Count Assay 
 
                      The standard method for enumerating CD4 T cells uses a flow 
cytometer. Computer calculates the number of CD4 T cells by analyzing the 
size of the cell and which of the antibodies it has been tagged with. The 
overall process is called Fluorescence Activated Cell Sorting (FACS). 
  
IMAGING 
Chest Skiagram 
                  An erect X-ray of the chest on deep inspiration in the 
posteroanterior view was taken for all patients.  
 
 Echocardiography  
                  Two dimensional Echocardiography was done for all patients 
included in this study in Department of Cardiology, Thanjavur Medical 
College Hospital, Thanjavur. 
 Chi square test was applied for significance. “P” value less than 0.05 
was considered as significant. 
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REFERENCE VALUE USED IN THIS STUDY 
 BMI (WHO criteria for Asian population)  
 Body Mass Index = Weight (kg) / Height in meter 2 
 Values      18.5 - 22.9 kg / m2 was taken as normal weight  
                    < 18.5 kg / m2 was taken as underweight  
                     23- 29.9 kg / m2 was taken as overweight 
                     ≥ 30 kg / m2 was taken as obesity 
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RESULTS 
1. A total of 100 patients were studied of which 8 patients were excluded 
from the study. Their stage of infection was noted and divide accordingly 
into four groups. 
2. There were 13 HIV seropositive patients in Stage I ,27 patients in Stage 
II,33 patients in Stage III  and 19 patients in Stage IV. 
3. The mean CD4 count of study population was 500.07± 334.37    . 
( Stage I- 690.38±464.62 
  Stage II-614.67±304.60 
  Stage III-346.63±252.68 
  Stage IV-516.06±292.62) 
4. Out of 92 patients,58 (63%) were males  (Stage I — 10    Stage II — 16    
Stage III — 17 Stage IV — 15) and 34 (37%) were females (Stage I —  3    
Stage II — 11  Stage III — 16 Stage IV  — 4) 
5.Mean age of study group was 43±11 (Stage I — 40±11   Stage II — 44 ±11 
Stage III — 42±12 Stage IV  —44±12) 
6. Unskilled labourers and house wives constituted the majority of the study 
population , about 34.8% and 22.8%  respectively 
7. Heterosexual route was the most common mode of transmission of HIV 
infection about 96.7%.  
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8. Mean duration of HIV infection was 3.53 ± 2.30 years. 
     (Stage I — 3.31±2.25 years Stage II — 3.71±2.34 years Stage III — 
3.46±2.43 years Stage IV  —3.55±2.22 years) 
9. Smokers and alcoholics constituted 20.6% (19 patients) and  48.91% (45 
patients) of the study population respectively. 
10.Mean BMI was 19.18±1.85 kg / m2 
(Stage I —19.22±2.3  kg / m2 
Stage II — 19.33±1.85 kg / m2  
Stage III — 19.12±1.55 kg / m2 
Stage IV  —19.03±2.12 kg / m2. 
 
11. Most patients were asymptomatic. Cardiac symptoms were found in 6 
patients(6.52%). 
(Stage I —0 
Stage II — 1 
Stage III —2 
Stage IV  —3) 
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12. Cardiac abnormalities either in the form of Electrocardiography or 
Echocardiography abnormality was found in 30 patients(32.60%) 
(Stage I —1 
Stage II —7 
Stage III —11 
Stage IV -11) 
13. Twenty patients (21.73%)had Electrocardiographic abnormalities 
(Stage I —1 
Stage II -3 
Stage III —8 
Stage IV  —8) 
14. Echocardiography abnormality was seen in 18 (19.56%) patients. 
(Stage I —0 
Stage II —4 
Stage III —5 
Stage IV  —9) 
15. Out of the 92 patients, 83 patients were on ZLN regimen and 9 patients 
were on TLE regimen. 
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16. Significant correlation was found between Stage of infection,CD4 count 
and duration of HIV infection with cardiac abnormalities. 
 
17. There was no significant correlation between age, sex, BMI, cardiac 
symptoms, type of HAART regimen, smoking and alcohol with cardiac 
abnormalities 
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STAGE OF INFECTION: 
TABLE 5 
 
 
 
 
 
                                      
 
      
 
 
    Stage I included 14.1% of patients 
     Stage II included 29.3 % of patients 
     Stage III and Stage IV included 35.9% and 20.7% of patients respectively.  
 
 
 
 
STAGE OF 
INFECTION 
NO. OF 
PATIENTS 
Percentage 
(100%) 
I 13 14.1 
II 27 29.3 
III 33 35.9 
IV 19 20.7 
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CARDIAC ABNORMALITIES: 
TABLE 6 
 
 
 Cardiac abnormalities either in the form of electrocardiography or 
echocardiography abnormality were found in  30 patients out of the total 92 
patients.The prevalence of cardiac abnormalities was 32.60%. 
 
 
 
 
 
 
CARDIAC ABNORMALITIES NUMBER OF PATIENTS 
PRESENT 30(32.60%) 
ABSENT 62(67.40%) 
TOTAL 92 
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CD 4 COUNTS: 
TABLE 7 
 
 
 
 
 
 
 
 
 
 
The mean CD4 count of study population was 500.07± 334.37. 
 
 
  
 
 
 
 
STAGE OF INFECTION MEAN CD4 COUNT cells / mm3 
I 690.38±464.62 
II 614.67±304.60 
III 346.63±252.68 
IV 516.06±292.62 
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STAGE OF INFECTION AND CARDIAC ABNORMALITIES: 
 
TABLE 8: 
 
 
There was a statistically significant correlation observed between Stage 
of infection and cardiac abnormalities. Prevalence of cardiac abnormalities 
increased with stage of infection. P value was 0.02(<0.05) 
 
 
 
STAGE OF 
INFECTION 
CARDIAC ABNORMALITIES 
TOTAL 
PRESENT ABSENT 
I 1 12 13 
II 7 20 27 
III 11 22 33 
IV 11 8 19 
TOTAL 30 62 92 
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AGE DISTRIBUTION IN RELATION TO CARDIAC 
ABNORMALITIES AND STAGE OF INFECTION: 
TABLE 9 
 
Mean age in study population was 43±11 years.  
Mean age in Stage I was 40 ±11. 
Mean age in Stage II was 44±11years. 
Mean age in Stage III was 42± 12 YEARS. 
Mean age in Stage IV was 44±12 YEARS 
 
 
 
STAGE OF INFECTION MEAN AGE 
I 40±11 
II 44 ±11 
III 42±12 
IV 44±12 
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TABLE 10 
 
There was no statistically significant correlation noted between age and cardiac abnormalities (P > 0.05). 
  
AGE IN 
YEARS 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES 
CARDIAC 
ABNORMALITIES 
Present Absent Total Present Absent Total Present Absent Total Present Absent Total 
20-25 1 (7.7%) 
0 1 
(7.7%) 
0 0 0 0 1 
(3.0%) 
1 
(3.0%) 
0 1 
(5.2%) 
1 
(5.2%) 
26-30 0 1 (7.7%) 
1 
(7.7%) 
2 (7.4%) 1 
(3.7%) 
3 
(11.1%) 
4 3 
(9.0%) 
7 
(21.2%) 
2 
(10.5%) 
1 
(5.2%) 
3 
(15.8%) 
31-35 0 2 (15.4%) 
2 
(15.4%) 
1 
(3.7%) 
3 
(11.1%) 
4 
(14.8%) 
1 
(3.0%) 
3 
(9.0%) 
4 
(12.1%) 
0 2 
(10.5%) 
2 
(10.5%) 
36-40 0 4 (30.8 %) 
4 
(30.8 %) 
2 
(7.4%) 
4 
(14.8%) 
6 
(22.2%) 
1 
(3.0%) 
2 
(6.0%) 
3 
(9.0%) 
2 
(10.5%) 
0 2 
(10.5%) 
≥41
 
0 5 
(38.5%) 
5 
(38.5%) 
2 
(7.4%) 
12(44.4) 14 
(51.9%) 
5 
(15.1%) 
13 
(13.4%) 
18 
(54.6%) 
7 
(21.2%) 
4 
(21.0%) 
11 
(57.9%) 
TOTAL 1 (7.7%) 
12 
(92.3%) 
13 
(100%) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 
11 
(33.3%) 
22 
(66.7%) 
33 
(100%) 
11 
(57.9%) 
8 
(42.1%) 
19 
(100%) 
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SEX DISTRIBUTION IN RELATION TO CARDIAC ABNORMALITIES AND STAGE OF INFECTION: 
TABLE 11: 
 
There was no statistically significant correla tion noted between sex and cardiac abnormalities(P > 0.05)
SEX 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES 
CARDIAC 
ABNORMALITIES 
CARDIAC 
ABNORMALITIES 
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MALE 1 (7.7 %) 
9 
(69.2%) 
 
10 
(76.9%) 
6 
(22.2%) 
10 
(37.0%) 
16 
(59.2%) 
3 
(9.0%) 
14 
(42.4 
17 
(51.5%) 
8 
(42.1%) 
7 
(36.8%) 
15 
(78.9%) 
FEMALE 0 3 (23.0%) 
3 
(23.0%) 
1 
(3.7%) 
10 
(37.0%) 
11 
(40.7%) 8 (24.2%) 
8 
(24.2%) 
16 
(48.5%) 
3 
(15.8%) 
1 
(5.2%) 
4 
(21.0%) 
TOTAL 1 (7.7 %) 
12 
(92.3%) 
13 
(100%) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 11(33.3%) 
22 
(66.7%) 
33 
(100%) 
11 
(33.3%) 
8 
(42.1%) 
19 
(100%) 
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OCCUPATION: 
TABLE 12: 
 
 
 
 
 
 
 
ROUTE OF TRANSMISSION: 
TABLE 13 
ROUTE OF TRANSMISSION TOTAL Percentage (100%) 
Heterosexual 89 96.7 
Homosexual 2 2.2 
IV Drug user 1 1.1 
Bisexual 0 0 
Blood transfusion 0 0 
 
 
 
OCCUPATION TOTAL 
House wife 21(22.8%) 
Lorry driver 4(4.3%) 
Office worker 18(19.6%) 
Sex worker 1(1.1%) 
Skilled labourer 16(17.4%) 
Unskilled labourer 32(34.8%) 
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BMI IN RELATION TO CARDIAC ABNORMALITIES AND STAGE 
OF INFECTION:    
TABLE 14: 
 
 
 
 
 
 
Mean BMI in study group was 19.18±1.84 kg / m2. 
Mean BMI in Stage I ,Stage II, Stage III and Stage IV was  19.22±2.3  kg / 
m
2.
 ,19.33±1.85  kg / m2.,19.12±1.55 kg / m2.and 19.03±2.12 kg / m2  
respectively 
 
 
 
 
STAGE OF INFECTION MEAN BMI 
I 19.22±2.3 
II 19.33±1.85 
III 19.12±1.55 
IV 19.03±2.12 
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TABLE 15 
 
There was statistically no significant correlation noted between BMI and cardiac abnormalities (P > 0.05). 
BMI 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC 
ABNORMALITIES CARDIAC ABNORMALITIES 
CARDIAC 
ABNORMALITIES CARDIAC ABNORMALITIES 
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UNDER WEIGHT 0 6 (46.2%) 
6 
(46.2%) 
2 
(7.4%) 
8 
(29.6%) 
10 
(37.0%) 
3 
(9.0%) 
7 
(21.2%) 
10 
(30.3%) 
5 
(26.3%) 
5 
(26.3%) 
10 
(52.6%) 
NORMAL 1 (7.7%) 
5 
(38.5%) 
 
6 
(46.2%) 
4 
(14.8%) 
12 
(44.4%) 
16 
(59.2%) 
7 
(21.1%) 
15 
(45.6%) 
22 
(66.7%) 
6 
(31.6%) 
2 
(15.8%) 
8 
(42.1%) 
OVER WEIGHT 0 1 (7.7%) 
1 
(7.7%) 
1 
(3.7%) 0 
1 
(3.7%) 
1 
(9.0%) 0 
1 
(9.0%) 0 
1 
(5.2%) 
1 
(5.2%) 
OBESE 0 0 0 0 0 0 0 0 0 0 0 0 
TOTAL 1 (7.7%) 
12 
(92.3%) 
13 
(100%) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 
 
11(33.3) 22 (66.7%) 
33 
(100%) 
11 
(57.9%) 
8 
(42.1%) 
19 
(100%) 
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CD4 COUNT IN RELATION TO CARDIAC ABNORMALITIES AND STAGE OF INFECTION: 
 
TABLE 16 
 
 
CD4 COUNT 
cells/cu.mm 
STAGE I STAGE II( STAGE III STAGE IV 
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES 
CARDIAC 
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< 200 0 1 (7.7%) 
1 
(7.7%) 
1 
(3.7%) 
1 
(3.7%) 
2 
(7.4%) 
7 
(21.3%) 
6 
(18.1%) 
13 
(39.3%) 
4 
(21.0%) 0 
4 
(21.4%) 
>=200 1 (7.7%) 
11 
(84.6%) 
12 
(92.3%) 
6 
(22.2%) 
19 
(70.3%) 
25 
(92.5%) 
 
4 
(12.1) 
16 
(48.4%) 
20 
(60.6%) 
7 
(36.8%) 
8 
(42.1%) 
15 
(78.9%) 
TOTAL 1 (7.7%) 
12 
(92.3%) 
13 
(100%) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 
11 
(33.3%) 
22 
(66.7%) 
33 
(100%) 
11 
(58.9%) 
8 
 
(42.1%) 
 
19 
(100%) 
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P value for stage I was 0.76 — statistically not significant 
P value for Stage II was 0.41 — statistically not significant 
P value for Stage III was 0.04 — statistically significant 
P value for Stage Iv was 0.04 — statistical significant 
There was a statistically significant correlation between cd 4 count and 
cardiac abnormalities in Stage III and Stage IV in contrast to Stage I and 
Stage II 
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DURATION OF HIV INFECTION IN RELATION TO CARDIAC 
ABNORMALITIES AND STAGE OF INFECTION 
Table 17 
STAGE OF 
INFECTION MEAN DURATION 
I 3.52±3.14 
II 3.34±2.22 
III 3.41±2.05 
IV 3.66 ±2.36 
 
Mean duration of HIV infection in study population was 3.53 ± 2.30 years. 
Mean duration of HIV infection in Stage I was 3.31±2.25 years. 
Mean duration of HIV infection in Stage II was 3.71±2.34 years. 
Mean duration of HIV infection in Stage III was 3.46±2.43 years 
Mean duration of HIV infection in Stage IV was 3.55±2.22 years 
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TABLE 18 
DURATION 
OF HIV 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
< 1 year 0 2 (15.4%) 
2 
(15.4%) 0 
3 
(11.1%) 
3 
(11.1%) 
1 
(3.0%) 
6 
(18.1%) 
7 
(21.2%) 0 
3 
(15.8%) 
3 
(15.8%) 
1- 3 years 0 5 (38.5%) 
5 
(38.5%) 0 
7 
(25.9%) 
7 
(25.9%) 
2 
(6.0%) 
8 
(24.2%) 
10 
(30.3%) 
3 
(15.8%) 
3 
(15.8%) 
6 
(31.6%) 
>3 years 1 (7.7%) 
5 
(38.5%) 
6 
(46.1%) 
7 
(25.9%) 
10 
(37.0%) 
17 
(62.9%) 
8 
(24.2%) 
8 
(24.2%) 
16 
(48.5%) 
8 
(42.1%) 
2 
(10.5%) 
10 
(52.6%) 
TOTAL 1 (7.7%) 12 
13 
(100%) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 11 
22 
(66.7%) 
33 
(100%) 
11 
(57.9%) 
8 
(42.1%) 
19 
(100%) 
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P value for stage I was 0.53 — statistically not significant 
P value for Stage II was 0.04— statistically significant 
P value for Stage III was 0.01— statistically significant 
P value for Stage Iv was 0.04 — statistical significant 
There was a statistically significant correlation between duration of infection 
and cardiac abnormalities in Stage II, Stage III and Stage IV in contrast to 
Stage I 
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SMOKING IN RELATION TO CARDIAC ABNORMALITIES AND STAGE OF INFECTION: 
TABLE 19 
CARDIAC 
SYMPTOMS 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC 
ABNORMALITIES 
CARDIAC 
ABNORMALITIES 
CARDIAC 
ABNORMALITIES CARDIAC ABNORMALITIES 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
P
R
E
S
E
N
T
 
A
B
S
E
N
T
 
T
O
T
A
L
 
PRESENT 0 0 0 0 1 (3.7%) 
1 
(3.7%) 0 
2 
(12.1%) 
2 
(12.1%) 
2 
(10.5%) 
1 
(5.2%) 
3 
(15.8%) 
ABSENT 1 (7.7%) 
12 
(92.3%) 
13 
(100%) 
7 
(25.9%) 
19 
(70.3%) 
26 
(96.2%) 
11 
(33.3%) 
20 
(60.6%) 
31 
(93.9%) 
9 
(47%.3%
) 
7 
(36.8%) 
16 
(84.2%) 
TOTAL 1 (7.7%) 
12 
(92.3%) 
13 
(100%) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 
11 
(33.3%) 
20 
(60.6%) 
33 
(100%) 
11 
(57.9%) 
8 
(42.1%) 
19 
(100%) 
 
There was no statistically significant correlation noted between smoking and cardiac abnormalities(p value>0.05) 
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ALCOHOL IN RELATION TO CARDIAC ABNORMALITIES AND STAGE OF INFECTION: 
TABLE 20 
ALCOHOL 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES 
P
R
E
S
E
N
T
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B
S
E
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T
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T
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L
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S
E
N
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A
B
S
E
N
T
 
T
O
T
A
L
 
PRESENT 1 (7.7%) 
7 
(53.8%) 
8 
(61.5%) 
6 
(22.2%) 
9 
(33.3%) 
15 
(55.6%) 
2 
(6.0%) 
9 
(27.3%) 
11 
(33.3%) 
7 
(36.8%) 
4 
(21.0%) 
11 
(57.9%) 
ABSENT 0 5 (38.4%) 
5 
(38.4%) 
1 
(3.7%) 
11 
(40.7%) 
12 
(44.4%) 
9 
(27.2) 
13 
(39.4%) 
22 
(66.7%) 
4 
(21.0%) 
4 
(21.0%) 
8 
(42.1%) 
TOTAL 1 (7.7%) 
12 
(92.3%) 
13 
(100%) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 
11 
(33.3%) 
22 
(66.7%) 
33 
(100%) 
11 
(57.9%) 
8 
(42.1%) 
19 
(100%) 
 
There was no statistically significant correlation noted between alcohol and cardiac abnormalities (P > 0.05). 
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CARDIAC SYMPTOMS IN RELATION TO CARDIAC ABNORMALITIES AND STAGE OF INFECTION: 
TABLE 21 
 
ALCOHOL 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES 
P
R
E
S
E
N
T
 
A
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T
 
T
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PRESENT 1 (7.7%) 
7 
(53.8%) 
8 
(61.5%) 
6 
(22.2%) 
9 
(33.3%) 
15 
(55.6%) 
2 
(6.0%) 
9 
(27.2%) 
11 
(33.3%) 
7 
(36.8%) 
4%) 
(21.0%) 
11 
(57.9%) 
ABSENT 0 5 (38.5%) 
5 
(38.5% 
1 
(3.7%) 
11 
(40.7%) 
12 
(44.4%) 
9 
(27.2%) 
13 
(39.3%) 
22 
(66.7%) 
4 
(21.0%) 
4 
(21.0%) 
8 
(42.1%) 
TOTAL 1 (7.7%) 
12 
(92.3%) 
13 
(100) 
7 
(25.9%) 
20 
(74.0%) 
27 
(100%) 
11 
(33.3%) 
22 
(66.7%) 
33 
(100%) 
11 
(57.9%) 
8 
(42.1%) 
19 
(100%) 
 
                   
There was no  statistically significant correlation found between cardiac symptoms and cardiac abnormalities 
( p value > 0.05).
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ANALYSIS OF ELECTROCARDIOGRAM: 
TABLE 22 
ECG 
Abnormalities 
STAGE 
I 
STAGE 
II 
STAGE 
III 
STAGE 
IV TOTAL 
Sinus tachycardia 1 (5%) 0 0 
1 
(5%) 2 
Conduction 
abnormalities 0 
1 
(5%) 
1 
(5%) 0 2 
Atrial ectopic 0 1 (5%) 
1 
(5%) 
1 
(5%) 3 
Ventricular ectopic 0 0 1 (5%) 0 1 
Poor progression of 
R wave 0 0 
3 
(15%) 
2 
(10%) 5 
Low voltage 0 0 0 3 (15%) 3 
ST/ T wave 
abnormality 0 
1 
(5%) 
2 
(10%) 
1 
(5%) 4 
Total 1 3 8 8 20 
 
Out of 92 patients,20 patients had ECG abnormalities. 
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ELECTROCARDIOGRAPHIC CHANGES IN RELATION TO STAGE 
OF INFECTION: 
TABLE 23 
ELECTRO 
CARDIOGRAPHY STAGE I STAGE II STAGE III  STAGE IV TOTAL 
NORMAL 12 24 25 11 72 
ABNORMAL 1 3 8 8 20 
TOTAL 13 27 33 19 92 
 
There was statistically significant correlation noted 
regarding electrocardiographic abnormalities (P  value was 0.04) . 
Prevalence of electrocardiographic abnormalities increased with stage of 
infection. 
  
70 
 
ECHOCARDIOGRAPHIC CHANGES IN RELATION  
TO STAGE OF INFECTION: 
                                    Table 24 
ECHOCARDIOGRAPHY STAGE I STAGE II STAGE III STAGE IV TOTAL 
Pericardial Effusion 0 0 0 1 (5.6%) 1 
Dilated Cardiomyopathy 0 0 2 (11.1%) 
1 
(5.6%) 3 
Hypokinesia and diasto;ic 
dysfunction 0 0 
2 
(11.1%) 
2 
(11.1%) 4 
Infective Endocarditis 0 0 0 1 (5.6%) 1 
diastolic dysfunction 0 2 (11.1%) 0 
4 
(22.2%) 8 
PHT 0 0 1 (5.6%) 0 1 
TOTAL 0 2 5 9 18 
 
Out of 92 patients ,16 patients had echocardiographic findings 
There was a statistically significant difference noted regarding  
echocardiographic abnormalities (P value was 0.00).Prevalence of 
echocardiographic abnormalities increased with stage of infection 
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TYPE OF HAART REGIMEN IN RELATION TO CARDIAC 
ABNORMALITIES AND STAGE OF INFECTION: 
HAART 
REGIMEN 
STAGE I STAGE II STAGE III STAGE IV 
CARDIAC 
ABNORMALITIES 
CARDIAC 
ABNORMALITIES 
CARDIAC 
ABNORMALITIES 
CARDIAC 
ABNORMALITIES 
PR
ES
EN
T 
A
B
SE
N
T 
TO
TA
L 
PR
ES
EN
T 
A
B
SE
N
T 
TO
TA
L 
PR
ES
EN
T 
A
B
SE
N
T 
TO
TA
L 
PR
ES
EN
T 
A
B
SE
N
T 
TO
TA
L 
ZLN 0 13 13 7 20 27 8 19 27 11 6 17 
TLE 0 0 0 0 0 0 3 3 6 0 2 2 
TOTAL 0 13 13 7 20 27 11 21 33 11 8 19 
 
Of the 92 patients,8 patients were on  TLE regimen while the remaining 84 patients 
were on ZLN regimen.Of the 84 patients on ZLN 7 patients in Stage II,8 patients in Stage 
III and 11 patients in Stage IV had cardiac abnormalities.Three patients out of the 8 
patients on TLE regimen had cardiac abnormalities either in the form of ECG or 
echocardiographic findings.P value was more than 0.05 and there was no statistically 
significant correlation noted between the type of regimen and cardiac abnormalities. 
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DISCUSSION 
Cardiovascular manifestations of HIV infection have not attracted 
much attention in the Indian sub continent. This is partly because of the 
clinical picture of HIV infection still dominated by opportunistic infections 
and symptoms of breathlessness, fatigue and poor exercise intolerance are 
frequently ascribed to other conditions associated with HIV infection. With 
the greater access to Anti-retroviral medications more patients may live 
longer enough to present with end organ disorders. Our study throws light 
into various unsuspected cardiac abnormalities in various groups of HIV 
infected patients and its relationship to CD4 count. 
A study conducted by Kannagai et al
57
at CMC Vellore in 2008 has 
shown that majority of the HIV infected individuals in South India with CD4 
counts of 200 - 350 cells / mm3 had higher viral load than that suggested by 
International AIDS Society. 
 
AGE DISTRIBUTION 
Our study population consisted of 100 patients. The mean age of our 
study group was Mean age in study population was 43±11 years. Mean age in 
Stage I, Stage II, Stage III and Stage IV was 40±11 years, 44 ±11 years, 
42±12 and 44±12 respectively with the age group ranging from 22 to75 
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years.. In a study conducted by Joshi et al at Mumbai,
59
 the age group ranged 
from 17 to 52 years with the mean age of 29.8 years. 
 
Correlation between age, stage of infection,and cardiac abnormalities 
was attempted. In Stage I, only one patient had cardiac abnormality and 
presented in the 20 - 25 years age group.. In Stage II, out of 7 patients with 
cardiac abnormalities 0 patient was in 20 - 25 years age group,two patients 
each in  26 -30 years group 36 - 40years age group and ≥41age group and 1 
patient in 31 - 35 years of age group . In Stage III, out of 11 patients with 
cardiac abnormalities 0 patient was in 20 - 25 years age group, 4 patients 
were 26 - 30 years age group, 1 patient was in 31 - 35 years age group, 1 
patient was  in 36 - 40 years age group and 5 patients were in more than 40 
years of age group.In Stage IV, out of 7 patients with cardiac abnormalities 0 
patient was in 20 - 25 years age group, 2 patients were 26 - 30 years age 
group, 0 patient was in 31 - 35 years age group,2 patients was in 36 - 40 years 
age group and 7 patients were in more than 40 years of age group. 
 
P values of all the groups was > 0.05 which was statistically 
insignificant. There was no correlation between age and cardiac abnormalities 
in this study similar to the study conducted by Caggese et al.
60
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GENDER DISTRIBUTION 
The gender distribution demonstrated a majority of 58 (63%) of males 
compared to 34 (37%) of females. In a study conducted by Joshi et al 
59
, male 
and female ratio was 5.7:1 ( 63 males and 11 females). In P Kannan et al 
61
 
study males were 120 and females were 80. In El Hattoui et al 
62 
study males 
and females were 88 and 70 respectively. 
 
Sex distribution in relation to cardiac abnormalities and stage of 
infection was seen. In Stage I, 10 males and 3 females had cardiac 
abnormalities. In Stage II, 16 males and 11 females had cardiac 
abnormalities.In Stage III, 17 males and 16 females had cardiac 
abnormalities.In Stage IV, 15 males and 4 females had cardiac abnormalities. 
Sex did not play a significant role in cardiac abnormalities in HIV patients. 
 
OCCUPATION 
In our study group, unskilled labourers and house wives constituted 
majority of the population about 34.8% and 22.8% respectively. Skilled 
labourers were 16(17.4%), 4.3% was lorry driver, 19.6% was office workers 
and 1.1% was commercial sex worker. 
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ROUTE OF TRANSMISSION 
 
Most of the study population had heterosexual behaviour (96.7). Remaining 
were homosexual (2.2%), IV drug users (1.1%). In a study by Joshi et al, 
59
 
among 74 patients 58.1% were heterosexuals, 4.05% blood transfusion 
related, 2.7% IV drug users, 1.35% bisexuals and 20.27% had multiple risk 
factors. 
 
CD 4 COUNT 
In our study, 21.73% of patients had CD4 count <200 and 78.26% of 
patients had CD 4 count >200. In Stage I one patient had cardiac abnormality 
and had CD4 count >200,in Stage II cardiac abnormalities were present in 1 
patient with CD 4 count < 200 and 6 patients with CD 4 count > 200, in Stage 
III cardiac abnormalities were present in 7 patients with CD 4 count < 200 
and 4 patients with CD 4 count > 200, in Stage IV patients with cardiac 
abnormalities 4 patients had CD 4 count < 200 and 7 patients had CD 4 count 
> 200 . 
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RISK FACTORS 
In our study group, 20.65%  were smokers and 48.91% were alcoholic. 
 
In Stage I, 38.4% were smokers. In Stage II 11.11% were smokers. In 
Stage III,18.18% were smokers. In Stage IV 26.31% were smokers. P values 
for all the four stages were statistically insignificant. 
 
In Stage I,61.53% were alcoholics. In Stage II,55.55% were 
alcoholics.In Stage III,33.33% were alcoholics.In Stage IV,57.89% were 
alcoholics.In a study by Smith CJ et al,
63
 
among 394 patients 45% were 
smokers and 7% were alcoholics. There was no significant correlation 
between smoking and alcohol with cardiac abnormalities in our study. This 
finding correlated well with the study by Caggese et al.
60
 
 
DURATION OF HIV INFECTION 
In this study 30.43% of patients had duration of illness between 1 - 3 
years. 16.30% had less than a year and 53.26% had duration of > 3 years. The 
duration of illness ranged from 2 months to 8.75years. Mean duration of 
illness in study population was 3.53± 2.31 years.  
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Mean duration of illness in Stage I,Stage II,Stage III,Stage IV were 
3.31±2.25  years , 3.71±2.34 years, 3.46±2.43 years and 3.55±2.22 years 
respectively. In a study by P Kannan et al, 
61
 the duration of illness ranged 
from 6 months to 7 years. 
 
 In Stage I, the duration was more than 3 years for the one patient who 
had cardiac abnormality . P value was 0.53, statistically insignificant. In 
Stage II, among 7 patients with cardiac abnormalities all the 7 patients had a 
duration of > 3 years. P value was 0.04, statistically significant. In Stage III, 
among 11 patients with cardiac abnormalities 8 patients had a duration of > 3 
years, 2 patient had a duration of 1 -3 years and 1 patient had a duration of 
less than a year.In Stage IV, among 11 patients with cardiac abnormalities 8 
patients had a duration of > 3 years, and 3 patients had a duration of 1 -3 
years.There was a significant correlation between duration of HIV infection 
and cardiac abnormalities in Stage II ,III and IV. 
 
SYMPTOMS 
Most patients were asymptomatic. Only 6 patients had cardiac 
symptoms (Stage I - 0, Stage II - 1, Stage III - 2 ,Stage IV-3). Among 26 
patients with cardiac abnormalities 6 patients had symptoms. The symptoms 
were dyspnea (10.7%),palpitation (1.3%) and chest pain (0.7%).  
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There was no significant correlation was found between cardiac 
abnormalities and cardiac symptoms. P values for all the stages were >0.05. 
In a study by Cardosa JS et al, 64 7.3% (10 / 137) of patients were 
symptomatic. In a study by Ewig S et al, 65 nine out of 14 patients (64%) 
with cardiac abnormalities had symptoms. 
BMI 
The mean BMI of our study group was 19.18±1.84 kg / m
2
.
 The mean 
BMI of Stage I,Stage II,Stage III, and Stage IV were 19.22±2.3  kg /m
2
, 
19.33±1.85  kg / m2.,19.12±1.55 kg / m
2
.
and 19.03±2.12 respectively.  
 
In Stage I, one patient who had cardiac abnormality had normal BMI.. In 
Stage II, out of 7 patients with cardiac abnormalities, 4 patients had normal 
BMI,two patients were underweight and  one patient was overweight.  In 
Stage III, out of 11 patients with cardiac abnormalities, 7 patients had normal 
BMI,three patients were underweight and  one patient was overweight.In 
Stage IV, out of 7 patients with cardiac abnormalities,4 patients had normal 
BMI and three patients were underweight. P values for all the stages were 
more than 0.05 and statistically insignificant. There was no significant 
correlation between BMI and cardiac abnormalities. 
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ELECTROCARDIOGRAPHIC ABNORMALITIES 
Electrocardiographic abnormalities were seen in 20 patients (21.73%). 
Twelve Patients had ECG abnormalities without echocardiographic 
abnormalities. Ten patients had normal ECG inspite of echocardiographic 
abnormality. In Stage I,one patient had ecg abnormality. In Stage II, 3 
patients had ECG abnormalities.In Stage III and IV, 8 patients had cardiac 
abnormalities respectively. The ECG abnormalities observed were  poor 
progression of R wave (25%), ST-T changes (20%), atrial ectopic (15%),low 
voltage complexes(15%),conduction abnormality (10%), sinus tachycardia 
(10%), and ventricular ectopic (5%).There was a significant correlation 
between CD4 count and ECG abnormalities (P value was 0.04). In a study by 
Herdy GV et al, 
67
 
out of 50 patients 18 patients had sinus tachycardia, 10 
patients had ST-T changes, 5 patients had low voltage complexes, 5 patients 
had ST segment elevation and 3 patients had extra systole. In Mirri A et al 
68
 
study, ECG abnormalities unrelated to echocardiographic abnormalities or 
clinical problems were seen in 11 patients. In Joshi et al 
59 
study, among 74 
patients, 20.27% had ECG abnormalities. 
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ECHOCARDIOGRAPHIC ABNORMALITIES 
Prevalence of cardiac abnormalities by echocardiography in our study 
was 19.56%. (22.22% in Stage II,27.77% in Stage III and 50% in Stage IV) 
Echocardiographic findings were diastolic dysfunction (44.44%),hypokinesia 
and diastolic dysfunction(22.22%) , dilated cardiomyopathy (16.66%), 
pericardial effusion (5.55%),pulmonary hypertension(5.55%)and infective 
endocarditis (5.55%). P value was 0.000, statistically significant.  
There was a significant correlation CD4 count and echocardiographic 
abnormalities. In a study by Joshi et al,
59
 
among 74 patients 10.6% had 
dilated cardiomyopathy, 8.5% had pericardial effusion, 4.2% had vegetations, 
2.1% had constrictive pericarditis and 10.6% had incidental valvular, left 
ventricular hypertrophy, ischemic heart disease. In a study by Mishra et al 
69
 
at AIIMS, 36.7% had diastolic dysfunction and 23.3% had systolic 
dysfunction. In P Kannan et al 
61
 
study, out of 200 patients, 28 patients had 
left ventricular dysfunction, 20 patients had pericardial effusion, 6 patients 
had pulmonary hypertension and one patient had dilated cardiomyopathy. In 
Mirri A et al 
68
 
study, 17% had echocardiographic abnormalities. 
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CARDIAC ABNORMALITIES 
In our study among 100 patients, 30 patients (32.60%) had cardiac 
abnormalities either in the form of ECG or Echocardiography abnormality. It 
is observed that 1 patient out of 13 patients (7.69%) in Stage I ,7 patients out 
of 27 (25.92%) patients in Stage II, 11 patients out of 33 (33.33%) patients in 
Stage III and 11 patients out of 27 (40.74%) patients in Stage IV had cardiac 
abnormalities. There was a statistically significant correlation between 
cardiac abnormalities and CD4 count (P value was 0.02). As the stage of 
infection increases, the cardiac abnormalities increase proportionally. Cardiac 
abnormalities are directly proportional to the Stage of infection. 
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SUMMARY 
The present study aimed at estimating the prevalence of cardiac 
abnormalities in HIV seropositive patients and also to find out its correlation 
with stage of infection. With rigid criteria 100 HIV seropositive cases were 
selected. There were 58 males and 34 females in the study group. 
Prevalence of cardiac abnormalities was 32.60% in our study. 
Diastolic dysfunction was the most common echocardiographic abnormality. 
Poor progression of R waves was the most common electrocardiographic 
abnormality. 
Cardiac abnormalities were specifically correlated with Stage of 
infection. Present study recommends screening for cardiac abnormalities in 
HIV patients to identify early cardiac involvement and minimize cardiac 
complications by early intervention. 
People with cardiac abnormalities did not necessarily have cardiac 
symptoms and the frequency of cardiac symptoms did not correlate with the 
stage of infection in this study. Cardiac symptoms in HIV infected individuals 
are likely to be attributed to other concurrent illnesses and the cardiac 
abnormalities remain undiagnosed further contriburting to the morbidity and 
mortality of HIv patients. 
Cardiac abnormalities correlated with the increase in the duration of 
infection and the decline in CD 4 count. 
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CONCLUSION 
 
1. The determination of Incidence and Prevalence of cardiac abnormalities in 
HIV infected individuals using non invasive tests is quite feasible and 
should be done in all patients registering in ART centre. 
2. There was a direct correlation between stage of infection and cardiac 
abnormalities.  
3. There was a significant correlation between duration of HIV infection and 
cardiac abnormalities. Prevalence of cardiac abnormalities was found to 
be more with increase in the duration of HIV infection. 
4. Most of the patients were asymptomatic.Correlation was not found 
between cardiac symptoms and cardiac abnormalities. 
5. Heterosexual route was the most common route of transmission of HIV.  
6. There was no significant correlation between age, sex, BMI, Type of 
HAART regimen,smoking and alcohol with cardiac abnormalities. 
7. The patients included in this study were on ART and correlation was not 
found between the type of HAART regimen and the cardiac 
abnormalities. Majority of patients were on ZLN regimen and the 
remaining were on TLE regimen. 
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LIMITATIONS 
 
1. The mean duration of the disease in our patients was less. This could be 
responsible for decreased incidence of cardiac abnormalities in our 
patients. 
2. Follow up study was not done. So the incidence of cardiac abnormalities in 
patients with previous normal echocardiography as well as the natural 
history of those who had Cardiac abnormality could not be studied. 
3. Since the critically ill patients were not included in our study the entire 
spectrum of cardiac abnormalities could not be established. 
5. Viral load could not be estimated due to constraints. 
6. Histopathologic studies like pericardial biopsy, endomyocardial biopsy and 
cytological study of pericardial fluid to determine the etiology of 
pericardial effusion and cardiomyopathy were not done. 
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RECOMMENDATIONS 
 
1. A baseline Echocardiographic study for all patients with HIV infection at 
first visit to be done. 
 
2. Echocardiographic follow up should be done to determine the evaluation of 
cardiac abnormalities and their reversibility with or without treatment. 
 
3. Histopathologic studies like pericardial biopsy, endomyocardial biopsy and 
cytological study of pericardial fluid to be done to determine the etiology 
of pericardial effusion and cardiomyopathy. 
 
4. Autopsy studies should be performed in patients dying of HIV associated 
illness and this will throw light on exact incidence of cardiac abnormalities 
in HIV infected patients. 
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ABBREVIATION 
AIDS - Acquired Immuno Deficiency Syndrome ANC - Antenatal clinic 
ART - Anti Retro Viral Therapy 
ATT - Anti Tuberculous Therapy 
BMI - Body Mass Index 
CD - Cluster Differentiation 
CNS - Central Nervous System 
CVS - Cardiovascular system 
DM - Diabetes Mellitus 
DNA - Deoxyribonucleic acid 
ECG - Electrocardiography 
Echo - Echocardiography 
FSW - Female Sex Worker 
HAART - Highly Active Anti Retro Viral Therapy HIV - Human 
Immunodeficiency Virus 
HT - Hypertension 
IDU - Intravenous Drug Users 
JVP - Jugular venous pressure 
LV - Left Ventricle 
MSM - Men having sex with men 
NACO  - National AIDS Control Organization  
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NACP  - National AIDS Control Programme  
NHL - Non Hodgkin’s Lymphoma OH - Orthostatic Hypotension RNA - 
Ribonucleic acid 
RS - Respiratory system 
STD - Sexually Transmitted Disease WHO - World Health Organization Kg - 
Kilo gram 
µL - Micro Litre 
mm
3 
- Cubic millimetre m2 - Metre square 
> - More than 
≥   - More than or Equal  
≤   - Less than or Equal  
< - Less than 
% - Percentage 
± - Plus or minus & - And 
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NAME AGE & SEX  OCCUPATION
 OPPORTUNISTIC 
INFECTION
MODE OF  
TRANSMISSION BMI SMOKER ALCOHOLIC DURATION HAART REGIMEN
CD4 COUNT 
- /cumm
 STAGE OF  
INFECTION CARDIAC SYMPTOMSECG ECHO
Sekar 48/M Unskilled labourer  PTB Heterosexual 18.19 Yes Yes 0.66 TLE 202 IV Yes Normal Normal
Sivnandham35/M Unskilled labourer NO Heterosexual 19.34 No Yes 1 ZLN 236 IV No Normal Normal
Arokyanantham49/M Lorry driver PTB Heterosexual 24 No No 2.5 ZLN 402 IV No Normal Normal
Gunasekaran51/M Skilled labourer No Heterosexual 17.2 No No 1.25 ZLN 1073 II No Normal Normal
Vasuki 30/F House wife No Heterosexual 23.42 No No 2 TLE 200 III No Normal Hypokinesia & Diastolic dysfunction
Palanivel 30/M Office worker No Heterosexual 16.84 No Yes 3.08 ZLN 479 II No Normal  Diastolic dysfunction
Vijaya 40/F House wife No Heterosexual 24.4 No No 4.08 ZLN 224 II No Atrial ectopic Normal
Isak 50/M Unskilled labourer No Heterosexual 21.86 Yes Yes 8.25 ZLN 450 III No Normal Normal
Elakkiya 28/F Sex worker No Heterosexual 22 No No 6.33 ZLN 694 IV No ST,T wave changes Dilated cardimyopathy
Kannadasan40/M Unskilled labourer No Heterosexual 20.46 No Yes 5.16 ZLN 124 II No Normal Diastolic Dysfunction
Chinnathal60/F House wife No Heterosexual 16.75 No No 2 ZLN 189 IV Yes Normal Pericardial effusion
Selvi 42/F Office worker NO Heterosexual 19.45 No No 0.41 ZLN 159 III No Normal mild PHT
Ramesh 47/M Lorry driver Herpes zoster IV Drug user 20.23 No Yes 0.75 ZLN 424 IV No Normal Normal
Rengasamy33/M Unskilled labourer No Heterosexual 26.2 No No 1.33 ZLN 381 I No Normal Normal
Ezhilmathi40/F Office worker No Heterosexual 17.43 No No 3.25 ZLN 396 II No Normal Normal
Sumathy 31/F Office worker No Heterosexual 19.76 No No 4 ZLN 479 II No Normal Normal
Jeeva 40/F House wife No Heterosexual 22.76 No No 2 ZLN 170 IV Yes Low voltage complexes Infective endocarditis
Chitra 29/F Skilled labourer No Heterosexual 20.2 No No 3.16 ZLN 189 II No Normal Normal
Indra 49/F House wife oral candidiasis Heterosexual 18.34 No No 1 ZLN 620 II No Normal Normal
Rosammal 70/F House wife PTB Heterosexual 17.11 No No 4.41 TLE 278 III No Poor progrssion of R wave Hypokinesia & Diastolic dysfunction
Ammakannu33/F House wife Herpes zoster Heterosexual 18.54 No No 1 ZLN 1311 II No Normal Normal
Vasantha 45/F Office worker No Heterosexual 20.87 No No 4.08 ZLN 709 II No Normal Normal
Radhakrishnan59/M Office worker No Heterosexual 16.77 Yes Yes 3.25 ZLN 804 IV No Normal Diastolic dysfunction
Premalatha46/F House wife oral candidiasis Heterosexual 19.88 No No 3 ZLN 466 II No Normal Normal
Nadesan 63/M Unskilled labourer No Heterosexual 18.37 No Yes 5.16 ZLN 425 II No Normal Normal
Selvi 39/F Office worker No Heterosexual 17.95 No No 0.16 ZLN 390 III No Normal Normal
Chinnathambi38/M Unskilled labourer No Heterosexual 18.72 No No 2.41 ZLN 252 I No Normal Normal
Segappi 40/F House wife No Heterosexual 21.53 No No 6.25 ZLN 120 III No ST,T wave changes Normal
Krishnaveni32/F Unskilled labourer No Heterosexual 16.83 No No 5.16 ZLN 345 III No Normal Normal
Govindasamy44/M Unskilled labourer No Heterosexual 18.37 Yes Yes 5.25 ZLN 166 IV No Low voltage complexes Diastolic dysfunction
Krishnasamy35/M office worker No Heterosexual 22.44 No Yes 0.58 ZLN 940 II No Normal Normal
Shanthi 32/F skilled labourer No Heterosexual 18.1 No No 3.58 ZLN 1091 I No Normal Normal
Bangaru 44/M unskilled labourer No Heterosexual 19.6 No Yes 5.08 ZLN 259 III No Normal NORMAL
Venmathi 30/F office worker No Heterosexual 16.53 No No 6.75 ZLN 552 III No Normal Normal
Dhanapal 34/M unskilled labourer No Heterosexual 19.65 Yes Yes 4 ZLN 778 II No Normal Diastolic dysfunction
Anbumani 40/M unskilled labourer PTB Heterosexual 18.98 No Yes 0.75 TLE 285 III No Normal Normal
Saraswati 40/F house wife No Heterosexual 19.29 No No 7.16 ZLN 1100 I No Normal Normal
Mani 38/M Skilled labourer No Heterosexual 17.9 No Yes 5 ZLN 445 IV No Poor progression of R wave Diastolic Dysfunction
Mala 40/F house wife Herpes zoster Heterosexual 21.78 No No 1.25 ZLN 254 II Yes Normal Normal
Raja 28/M Office worker No Heterosexual 17.53 No Yes 6 ZLN 965 II No RBBB Normal
Mary 30/F House wife No Heterosexual 16.99 No No 0.91 ZLN 623 III No Normal Normal
Saralmary 45/F Unskilled labourer oral candidiasis Heterosexual 20.31 No No 4.75 ZLN 521 III No Normal Normal
Rajendren 48/M Unskilled labourer No Heterosexual 20.55 Yes Yes 2.5 ZLN 947 III No Normal Normal
Pitchai 58/M Lorry driver No Heterosexual 19.24 No Yes 3 ZLN 120 IV No Poor progression of R wave Normal
Perumal 56/M Skilled labourer No Heterosexual 19.71 Yes No 6.16 ZLN 458 III No Normal Normal
Sarala 36/F House wife No Heterosexual 18.56 No No 0.66 ZLN 987 II No Normal Normal
Manikandan42/M Unskilled labourer PTB Heterosexual 19.77 No Yes 3.33 ZLN 759 III No Normal Normal
Rajesh 50/M Unskilled labourer No Heterosexual 20.31 Yes Yes 5.58 ZLN 954 IV No Normal Diastolic Dysfunction
Megala 45/F House wife No Heterosexual 19.69 No No 2 ZLN 854 III No Normal Normal
Saranya 28/F House wife No Heterosexual 20.06 No No 6.16 ZLN 114 III No LBBB Normal
Veerasamy75/M Unskilled labourer No Heterosexual 21.6 No Yes 8.75 ZLN 741 II No Normal Normal
Aravind 45/M Skilled labourer oral candidiasis Heterosexual 18.24 No Yes 4.33 ZLN 254 I No Normal Normal
Ayyapan 46/M Skilled labourer No Heterosexual 19.52 Yes No 0.41 ZLN 102 III No Normal Normal
Munusamy 58/M Unskilled labourer Herpes zoster Heterosexual 16.82 No Yes 7.91 TLE 354 III No Normal Normal
Vendhan 45/M Unskilled labourer No Heterosexual 19.82 No Yes 8.75 ZLN 258 II No Normal Normal
Santhanam28/M Unskilled labourer No Homosexual 17.62 No Yes 2.25 ZLN 325 I No Normal Normal
Arokiasamy40/M Skilled labourer No Heterosexual 19.5 Yes Yes 4.25 ZLN 654 II No Normal Normal
Muniyammal62/F House wife No Heterosexual 19.72 No No 7.25 ZLN 159 III No Poor progression of R wave Normal
Latha 45/F House wife PTB Heterosexual 19.65 No No 2 ZLN 257 III No Ventricular ectopic Normal
Malar 29/F House wife No Heterosexual 18.72 No No 0.25 ZLN 759 III No Normal Normal
Balasubramaian56/M Skilled labourer No Heterosexual 19.05 No No 3 ZLN 145 III No Normal Normal
Amutha 52/F House wife No Heterosexual 18.28 No No 3 ZLN 857 III No Normal Normal
Dhandapani56/M Lorry driver No Heterosexual 17.53 No Yes 6.58 ZLN 965 II No Normal Dilated cardiomyopathy
Mohan 22/M Skilled labourer Herpes zoster Heterosexual 20.63 Yes Yes 4.33 TLE 1452 I No Sinus tachycardia Normal
Shankar 36/M Skilled labourer No Heterosexual 18.48 No Yes 1 ZLN 125 I No Normal Normal
Muthulakshmi55/F House wife No Heterosexual 19.57 No No 0.42 ZLN 985 I No Normal Normal
Chinnaponnu56/F Unskilled labourer No Heterosexual 19.04 No No 2.83 ZLN 745 II No Normal Normal
Umarani 35/F House wife PTB Heterosexual 17.38 No No 6.25 ZLN 321 IV No Normal Normal
Seetha 29/F Unskilled labourer No Heterosexual 19.29 No No 3.91 TLE 154 III No Poor progression of R wave Dilated cardiomyopathy
Kumaresan64/M Unskilled labourer No Heterosexual 18.2 Yes Yes 6.83 ZLN 652 IV No Low voltage complexes Hypokinesia & Diastolic dysfunction
Ponnusamy44/M Unskilled labourer No Heterosexual 18.35 No No 0.5 ZLN 147 III No Normal Normal
Sivakumar 48/M Office worker PTB Heterosexual 19.5 No Yes 5.58 ZLN 841 IV No Atrial ectopic Normal
Abdul Latif22/M Office worker PTB Heterosexual 18.66 No Yes 1.83 TLE 64 III Yes Normal Normal
Peter 46/M Skilled labourer NO Heterosexual 16.78 Yes Yes 3 ZLN 255 I No Normal Normal
Gopinath 23/M Office worker No Heterosexual 19.64 No No 0.25 ZLN 987 IV No Normal Normal
Prabakaran55/M Unskilled labourer No Homosexual 19.57 No Yes 2 ZLN 485 II No Normal Normal
Ganesh 41/M Unskilled labourer No Heterosexual 18.24 No Yes 4 ZLN 652 II No Normal Normal
Anand 33/M Skilled labourer No Heterosexual 17.3 Yes No 2 ZLN 145 III No Normal Normal
Kalyana sundaram26/M Office worker Herpes zoster Heterosexual 19.29 No Yes 3.75 ZLN 254 III No Atrial ectopic Normal
Arivumani 55/M Office worker No Heterosexual 18.3 Yes Yes 6.33 ZLN 1256 I No Normal Normal
Paulraj 36/M Unskilled labourer PTB Heterosexual 18.54 Yes Yes 0.66 ZLN 1021 I No Normal Normal
Arumugam52/M Unskilled labourer No Heterosexual 18.64 No No 1.25 ZLN 144 III Yes Normal Normal
Valluvan 32/M Unskilled labourer No Heterosexual 20.61 No Yes 2.25 ZLN 285 III No Normal Normal
Karthikeyan55/M Skilled labourer No Heterosexual 19.45 Yes Yes 6.16 ZLN 478 I No Normal Normal
Aasaithambi29/M Unskilled labourer No Heterosexual 16.24 No Yes 5.75 TLE 285 IV No Normal Normal
Senthil kumar48/M Unskilled labourer No Heterosexual 16.87 No No 1.33 ZLN 547 IV No Normal Normal
Harish 54/M Office worker No Heterosexual 18.49 Yes Yes 0.42 ZLN 874 II No Normal Normal
Dhinakaran44/M Skilled labourer No Heterosexual 16.05 No Yes 6.75 ZLN 345 II No ST,T wave changes Normal
Ponnilavan57/M Skilled labourer No Heterosexual 19.82 No Yes 5.25 ZLN 458 II No Normal Normal
Arulkumar 26/M Office worker PTB Heterosexual 17.93 No No 4.25 ZLN 658 IV No Sinus tachycardia Hypokinesia & Diastolic dysfunction
Vijayan 31/M Office worker No Heterosexual 19.72 Yes Yes 3.66 ZLN 154 III No Normal Diastolic Dysfunction
John 47/M Unskilled labourer No Heterosexual 17.24 No Yes 6.5 ZLN 145 III No ST,T wave changes Normal
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